On September 19, MacroGenics Inc And Provention Bio Entered Into An Amendment Of Asset Purchase Agreement; Co And Aventis Inc Concurrently Entered Into Mutual Termination Agreement Terminating The Royalty Purchase Agreement
Portfolio Pulse from Benzinga Newsdesk
MacroGenics Inc and Provention Bio have amended their asset purchase agreement. Concurrently, MacroGenics and Aventis Inc have mutually terminated their royalty purchase agreement, according to an SEC filing.
September 22, 2023 | 8:47 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
MacroGenics has amended an asset purchase agreement with Provention Bio and terminated a royalty purchase agreement with Aventis. This could potentially impact the company's future revenues and financial stability.
The amendment of the asset purchase agreement could potentially change the financial dynamics between MacroGenics and Provention Bio, while the termination of the royalty purchase agreement with Aventis could impact MacroGenics' future royalty revenues. However, without specific details on the changes, the impact on the stock price is uncertain.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100